Neuro player Jazz Pharmaceuticals dives into immuno-oncology, inking cytokine pact with Werewolf
Jazz Pharmaceuticals and Werewolf Therapeutics are teaming up on a new immuno-oncology pact, one that could see Werewolf in line for more than a $1 billion payday.
The companies announced they are collaborating on WTX-613, a Werewolf-discovered interferon alpha compound currently in the preclinical phase. Jazz is ponying up $15 million in upfront cash and is promising up to $1.26 billion in milestones, should they all be reached. Werewolf can also receive tiered mid-single-digit percentage royalties on net sales.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.